Advancing Small-Molecule Discovery with AI: Boltz Gains Momentum AI-native drug discovery company Boltz has announced a $28 million seed financing alongside a strategic collaboration with Pfizer, marking a significant step…

Breakthrough in Small-Molecule Discovery Targets “Undruggable” Cancers A research team at UCLA Health Jonsson Comprehensive Cancer Center has identified a novel small molecule that could unlock an entirely new class…

Small-Molecule Drug Discovery in 2025 Where the Market Stands—and How Far It Could Grow by 2030–2035 Small molecules—typically orally available, chemically synthesized drugs—remain the workhorse modality of modern therapeutics. In…

AI-Driven Molecular Representation Advances Scaffold Hopping A New Era for Small-Molecule Drug Discovery Small-molecule therapeutics remain foundational to modern medicine, supporting treatment across oncology, immunology, cardiovascular disease, and CNS disorders.…

New Biocompatible Frameworks: Small-Molecule HOFs Open the Door to Advanced Bio-Applications In a notable advance that bridges chemistry, materials science, and biotechnology, researchers have developed a new class of highly…

Clusterin Enhancer Alzheimer’s Therapy: A Small-Molecule Approach   Researchers have identified a clusterin enhancer Alzheimer’s therapy based on a small-molecule drug candidate that boosts levels of a naturally protective brain…

IGF2BP3 Inhibitor I3IN-002 Shows Promise Against Hard-to-Treat Leukaemia Researchers have identified a small-molecule inhibitor of the RNA-binding protein IGF2BP3 that demonstrates potent anti-leukaemic activity in both cellular and animal models.…